Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Carisbamate (Primary)
- Indications Partial epilepsies
- Focus Registrational; Therapeutic Use
- Sponsors Janssen-Cilag
- 21 Feb 2013 New trial record